Bolt Biotherapeutics vs Prime Medicine
Bolt Biotherapeutics is the larger business, with $7.7m of revenue in fiscal 2025 against $4.6m for Prime Medicine (1.7 times as much). Prime Medicine grew faster (55.3% against 0.1%). Bolt Biotherapeutics kept more of each dollar of sales as profit: a net margin of -433.7% against -4342.4%. Bolt Biotherapeutics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Bolt BiotherapeuticsBOLT, 2025 | Prime MedicinePRME, 2025 |
|---|---|---|
| Revenue | $7.7m | $4.6m |
| Revenue growth | 0.1% | 55.3% |
| Net income | −$33.4m | −$201m |
| Operating margin | -469.3% | -4498.1% |
| Net margin | -433.7% | -4342.4% |
| Return on equity | -79.7% | -146.8% |
| Free cash flow | −$39.9m | −$167m |
| Cash | $11.7m | $63.0m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 23 | 146 |
| Market value | $12.7m | $807m |
| Price vs our value range | — | — |
| Moat score | 12 (Weak) | — |
| Insider trades, 12 months | 4 buys, 9 sales | 0 buys, 0 sales |